CIK 0001590877 · Non-accelerated filer<br>Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 471851754
- Phone
- 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- 4 Shares withheld for taxes Chief Strategy & Legal Officer gave up 4,700 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Medical Officer gave up 5,267 shares (to pay taxes)
- 4 Shares withheld for taxes Director gave up 221,753 shares (to pay taxes)
- 8-K Event Other events
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Grant or award Chief Medical Officer acquired 65,847 shares (grant or award)
- 4 Grant or award Chief Technology Officer acquired 65,847 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 144,864 shares (grant or award)
- 4 Grant or award Chief Strategy & Legal Officer acquired 73,749 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 73,749 shares (grant or award)
- 4 Shares withheld for taxes Chief Executive Officer gave up 18,559 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Technology Officer gave up 1,238 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Strategy & Legal Officer gave up 9,793 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Medical Officer gave up 18,247 shares (to pay taxes)
- EFFECT Other Notice of Effectiveness
- CORRESP Other Correspondence Between Filers and SEC Staff
- S-3 Offering Registration Statement
- 8-K Event Results of operations
- 10-Q Report Quarterly Report
- 4 Planned sale Chief Executive Officer sold 20,811 shares at $12.62 ($262,635)
Page 4 of 41 · 806 filings